CSL Behring News and Activities

CSL Behring is owned by CSL.

CSL is one of the...

• Forbes Global 2000 (#441);
• S&P/ASX200;
• TOB Iconic 10,000.

CSL is a company listed under the stock ticker CSL (AU).

CSL has a direct presence in 12 countries.

CSL has 17 subsidiaries including CSL Behring, CSL Behring APAC and CSL Behring Asia.

They are in:

• Pharmaceuticals50%
• Biotechnology39%
• Other11%

View the org chart displaying its 30 main executives

Most searched biographies at CSL Behring

• Paul McKenzie, Chief Executive Officer and Managing Director
• Tara Chapman, Executive Director and Head, Global Regulatory Affai...
• Michael Ruggiero, Senior Vice President, Global Policy, Advocacy &...

Popular executive movements at CSL

• Cameron Price has joined the company as Non-Executive Director  (posted on June 13 2025).

Create your alert
to follow the executive moves at CSL Behring.

CSL has 2,347 competitors including Incyte (United States (USA)), Anthos Therapeutics (United States (USA)) and Valneva (France).

Popular M&A news in Biotechnology

• The new name of Synaptogenix is TAO Synergies. (posted on July 3 2025).
• AbbVie has announced the acquisition of Capstan Therapeutics  (posted on July 1 2025).
• Neuron23 has just announced a $97 Million fundraising (posted on June 30 2025).

Popular contacts in Biotechnology

• Jasbir Seehra - Chief Executive Officer and Chairman of the Board at Keros Therapeutics
• Sandra Smith - Senior Vice President, Clinical Solutions & Strategic Partnerships at WIRB-Copernicus Group
• Andrea Jackson - Director at Ultivue

Learn more about the Biotechnology industry

Press releases by CSL Behring

• U.S. Food and Drug Administration Approves CSL's ANDEMBRY® (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once-Monthly Dosing for All Patients From the Start
• England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy
• CSL Behring wins 2025 International Society for Pharmaceutical Engineering (ISPE) Facility of the Year Award
• CSL Seqirus, a Global Leader in Pandemic Preparedness and Outbreak Response, Signs an Agreement with the European Commission to Support Pandemic Preparedness Plans
• CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy
• CSL Launches ANDEMBRY® for the Prevention of Acute Attacks in Hereditary Angioedema (HAE) in Japan
• Influenza cases already at highest to date with vaccines now available
• CSL Seqirus and Esperion Sign Licensing Agreement to commercialise Nexletol® (bempedoic acid) and Nexlizet® (bempedoic acid/ezetimibe) in Australia and New Zealand
• Swissmedic Approves CSL Behring’s ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE)
• European Commission Approves CSL's ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE)
• View more press releases Close

Social media about CSL Behring

• CSL Behring on Wikipedia, Google News & Yahoo Finance
• CSL Behring on LinkedIn, Twitter & YouTube